Anavex Life Sciences: Negative CHMP Decision Does Not Bode Well For Future Approval For Alzheimer's

Anavex Life Sciences' Phase 2B/3 trial failed to achieve statistical significance on both primary endpoints. Read why I ...

2026 Market Outlook: How An AGI Breakthrough Could Fuel An Actual AI Bubble

Discover how rapid AI advances could trigger an AGI-driven market bubble by 2026, reshape equities, and impact rates.

Master of Power - Chapter 2: A Dream of Snow

Optional Elite: On the west side of the area you can fight the Menacing Frost Bear. Its weaknesses are Sword, Axe, Bow, Tome, ...